New study published in Oncotarget by Dr. Carbone group

news on 8 Oct , 2016

The study, conducted by Dr. Giuseppina Carbone and collaborators in Experimental Therapeutics and Prostate Cancer Biology, demonstrates that the transcription factor ESE3/EHF controls the IL-6/JAK/STAT3 axis and shows that targeting this pathway is beneficial in aggressive prostate tumors with reduced ESE3/EHF activity.